Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

ABSTRACT Introduction Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP‐ribose) polymerase inhibitors. We analyzed real‐world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring germline BRCA mutations in Italy, where...

Full description

Saved in:
Bibliographic Details
Main Authors: Michele Milella, Giulia Orsi, Mariacristina diMarco, Lisa Salvatore, Letizia Procaccio, Silvia Noventa, Silvia Bozzarelli, Ingrid Garajova, Enrico Vasile, Guido Giordano, Marina Macchini, Alessandro Cavaliere, Marina Gaule, Francesca Bergamo, Marta Chiaravalli, Andrea Palloni, Riccardo Carloni, Alessandro Bittoni, Monica Niger, Ilario Giovanni Rapposelli, Maria Grazia Rodriquenz, Mario Scartozzi, Stefania Mosconi, Elisa Giommoni, Ilaria Bernardini, Chiara Paratore, Andrea Spallanzani, Katia Bencardino, Laura Forti, Emiliano Tamburini, Sara Lonardi, Aldo Scarpa, Stefano Cascinu, Giampaolo Tortora, Isabella Sperduti, Michele Reni
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Cancer Medicine
Subjects:
germline BRCA1/2 pathogenic variants
metastatic
olaparib
pancreatic cancer
poly(ADP‐ribose) polymerase inhibitors
real‐world experience
Online Access:https://doi.org/10.1002/cam4.70364
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1002/cam4.70364

Similar Items